174 related articles for article (PubMed ID: 8032635)
1. Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.
Böhm M; Weinhold C; Schwinger RH; Müller-Ehmsen J; Böhm D; Reichenspurner H; Reichart B; Erdmann E
Br J Pharmacol; 1994 May; 112(1):137-42. PubMed ID: 8032635
[TBL] [Abstract][Full Text] [Related]
2. Interaction of a series of draflazine analogues with equilibrative nucleoside transporters: species differences and transporter subtype selectivity.
Hammond JR
Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr; 361(4):373-82. PubMed ID: 10763851
[TBL] [Abstract][Full Text] [Related]
3. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine.
Snoeck E; Jacqmin P; Van Peer A; Danhof M; Ver Donck K; Van Belle H; Woestenborghs R; Crabbé R; Van Gool R; Dupont A; Heykants J
Br J Clin Pharmacol; 1996 Nov; 42(5):605-13. PubMed ID: 8951192
[TBL] [Abstract][Full Text] [Related]
4. Nucleoside transporter of pig erythrocytes. Kinetic properties, isolation and reaction with nitrobenzylthioinosine and dipyridamole.
Woffendin C; Plagemann PG
Biochim Biophys Acta; 1987 Sep; 903(1):18-30. PubMed ID: 3651452
[TBL] [Abstract][Full Text] [Related]
5. Effects of carbachol and (-)-N6-phenylisopropyladenosine on myocardial inositol phosphate content and force of contraction.
Kohl C; Linck B; Schmitz W; Scholz H; Scholz J; Tóth M
Br J Pharmacol; 1990 Dec; 101(4):829-34. PubMed ID: 2085707
[TBL] [Abstract][Full Text] [Related]
6. Chromatographic characterization of nitrobenzylthioinosine binding proteins in band 4.5 of human erythrocytes: purification of a 40 kDa truncated nucleoside transporter.
Jhun BH; Rampal AL; Berenski CJ; Jung CY
Biochim Biophys Acta; 1990 Oct; 1028(3):251-60. PubMed ID: 2223799
[TBL] [Abstract][Full Text] [Related]
7. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium.
Schwinger RH; Böhm M; Mittmann C; La Rosée K; Erdmann E
J Mol Cell Cardiol; 1991 Apr; 23(4):461-71. PubMed ID: 1658340
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte nucleoside transport: asymmetrical binding of nitrobenzylthioinosine to nucleoside permeation sites.
Jarvis SM; McBride D; Young JD
J Physiol; 1982 Mar; 324():31-46. PubMed ID: 7097603
[TBL] [Abstract][Full Text] [Related]
9. Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution.
Deighton NM; Motomura S; Borquez D; Zerkowski HR; Doetsch N; Brodde OE
Naunyn Schmiedebergs Arch Pharmacol; 1990; 341(1-2):14-21. PubMed ID: 2314479
[TBL] [Abstract][Full Text] [Related]
10. Interaction of the mioflazine derivative R75231 with the nucleoside transporter: evidence for positive cooperativity.
Jones KW; Hammond JR
Eur J Pharmacol; 1993 Jul; 246(2):97-104. PubMed ID: 8375464
[TBL] [Abstract][Full Text] [Related]
11. Effects of nucleoside transport inhibitors and adenine/ribose supply on ATP concentration and adenosine production in cardiac myocytes.
Kalsi KK; Smolenski RT; Yacoub MH
Mol Cell Biochem; 1998 Mar; 180(1-2):193-9. PubMed ID: 9546646
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016.
Beukers MW; Kerkhof CJ; IJzerman AP; Soudijn W
Eur J Pharmacol; 1994 Jan; 266(1):57-62. PubMed ID: 8137884
[TBL] [Abstract][Full Text] [Related]
13. Nucleoside transport in heart: species differences in nitrobenzylthioinosine binding, adenosine accumulation, and drug-induced potentiation of adenosine action.
Williams EF; Barker PH; Clanachan AS
Can J Physiol Pharmacol; 1984 Jan; 62(1):31-7. PubMed ID: 6713281
[TBL] [Abstract][Full Text] [Related]
14. Identification of the erythrocyte nucleoside transporter as a band 4.5 polypeptide. Photoaffinity labeling studies using nitrobenzylthioinosine.
Wu JS; Kwong FY; Jarvis SM; Young JD
J Biol Chem; 1983 Nov; 258(22):13745-51. PubMed ID: 6643450
[TBL] [Abstract][Full Text] [Related]
15. Identification of nucleoside transport binding sites in the human myocardium.
Abd-Elfattah AS; Hoehner J; Wechsler AS
Mol Cell Biochem; 1998 Mar; 180(1-2):105-10. PubMed ID: 9546636
[TBL] [Abstract][Full Text] [Related]
16. Comparison of nucleoside transport binding sites in rabbit iris-ciliary body and cultured rabbit nonpigmented ciliary epithelial cells.
Williams EF; Chu TC; Socci RR; Brown LG; Walker CE; Manor EL
J Ocul Pharmacol Ther; 1996; 12(4):461-9. PubMed ID: 8951682
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic cleavage of [3H]nitrobenzylthioinosine-labelled nucleoside transporter in human erythrocytes.
Janmohamed NS; Young JD; Jarvis SM
Biochem J; 1985 Sep; 230(3):777-84. PubMed ID: 4062878
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of nitrobenzylthioinosine binding to the human erythrocyte nucleoside transporter.
Jarvis SM; Janmohamed SN; Young JD
Biochem J; 1983 Dec; 216(3):661-7. PubMed ID: 6667262
[TBL] [Abstract][Full Text] [Related]
19. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine.
Snoeck E; Ver Donck K; Jacqmin P; Van Belle H; Dupont AG; Van Peer A; Danhof M
J Pharmacol Exp Ther; 1998 Jul; 286(1):142-9. PubMed ID: 9655853
[TBL] [Abstract][Full Text] [Related]
20. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium.
Schwinger RH; Böhm M; La Rosée K; Erdmann E
Am Heart J; 1992 Aug; 124(2):320-30. PubMed ID: 1322030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
